Methods for detecting sinusoidal obstructive syndrome (sos)
AssigneeIndiana University Research and Technology Corporation
InventorSophie PACZESNY
Life of this patent
Estimating the term…
Abstract
Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
Claims8
A method of detecting the expression level of a biomarker panel in a subject receiving hematopoietic cell transplantation (HCT), the method comprising
- measuring in a biological sample from the subject the expression of the biomarker panel comprising L-Ficolin, hyaluronic acid (HA) and IL-1RL1 (ST2) by contacting the biological sample obtained from the subject with at least a first agent that specifically binds to L-Ficolin, at least a second agent that specifically binds to HA, at least a third agent that specifically binds to ST2, wherein each specific binding agent forms a complex with the biomarker;
- and
- detecting the agent-biomarker complex, thereby determining the biomarker panel expression level.
A method of treating sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), said the method comprising
- identifying a patient at risk SOS by
- obtaining a biological sample from a subject receiving HSCT;
- measuring in said biological sample from the subject the expression of at least three biomarkers selected from the group consisting of L-Ficolin, hyaluronic acid (HA) and IL-1RL1 (ST2), and VCAM1 by contacting the biological sample obtained from the subject with specific binding agents that specifically bind to each of the respective the biomarkers, wherein the each specific binding agent forms a complex with the their respective biomarker;
- and
- detecting the agent-biomarker complexes, thereby determining the biomarker expression level;
- wherein an elevated biomarker expression level of said at least three biomarkers compared to biomarker expression obtained from a biological sample obtained from a control is indicative of SOS;
- and
- treating said patient at risk of SOS with defibrotide.
A diagnostic biomarker panel comprising an antibody that specifically binds to human IL-1RL1, an antibody that specifically binds to human L-Ficolin, and an antibody that specifically binds to human hyaluronic acid (HA).
Dependencies are inferred from the claim text.